UK markets closed
NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.79 -0.02 (-0.02%) GOLD FUTURES
2,329.10 -9.30 (-0.40%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,377.70 -1,861.33 (-3.50%)
GlaxoSmithKline plc (GLAXF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 09:50AM EDT
| Previous close | 19.54 |
| Open | 19.85 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 19.85 - 19.85 |
| 52-week range | 16.65 - 22.12 |
| Volume | |
| Avg. volume | 1,311 |
| Market cap | 84.222B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 13.41 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (4.11%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Zacks
GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- CityAM
US regulator accepts GSK’s application to expand treatment of cancer drug
The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.
- Fool.co.uk
Is this FTSE growth superstar set to soar even higher on new drug results?
New drugs should significantly boost this FTSE stock’s earnings in my view. But even without them it looked very undervalued to me. The post Is this FTSE growth superstar set to soar even higher on new drug results? appeared first on The Motley Fool UK.
© 2024 Yahoo. All rights reserved.